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Inhibitor of apoptosis proteins (IAPs) such as XIAP subvert apoptosis by binding and
inhibiting caspases. Because occupation of the XIAP BIR3 peptide binding pocket by Smac
abolishes the XIAP–caspase 9 interaction, it is a proapoptotic event of great therapeutic
interest. An assay for pocket binding was developed based on the displacement of Smac 7-mer
from BIR3. Through the physical and biochemical analysis of a variety of peptides, we have
determined the minimum sequence required for inhibition of the Smac–BIR3 interaction and
detailed the dimensions and topology of the BIR3 peptide binding pocket. This work describes
the structure–activity relationship (SAR) for peptide inhibitors of Smac-IAP binding.
KEY WORDS: BIR; cancer; caspases; inhibitors of apoptosis protein (IAP); peptidomimetics; protein–
protein interaction; Smac/DIABLO.
INTRODUCTION
Programmed cell death plays a critical role in
regulating cell number and in eliminating stressed or
damaged cells from normal tissues. Indeed, the net-
work of apoptotic signalling mechanisms inherent in
most cell types provides a major barrier to the
development and progression of human cancer. Since
most commonly used chemo and radiation therapies
rely on activation of apoptotic pathways to kill can-
cer cells, tumor cells which are capable of evading
programmed cell death are often diﬃcult to treat.
As the molecular circuitry underlying apoptotic
signalling is elucidated, the nature of these desensi-
tizing alterations are becoming better understood.
Apoptosis signalling networks are classiﬁed as either
intrinsic and mediated by cellular stress and
mitochondrial permeabilization or extrinsic and
mediated by death receptor–ligand interactions
(Ashkenazi and Dixit, 1998; Green and Reed, 1998).
Both pathways ultimately converge on caspases.
Once activated, caspases cleave a number of cell
death-related substrates, eﬀecting destruction of the
cell.
One strategy for evading apoptosis involves
upregulation of Inhibitor of Apoptosis (IAP) proteins
(Tamm et al., 2000, 2004; Hofmann et al., 2002;
Krajewska et al., 2003; Shiraki et al., 2003). Eight
IAP family members have thus far been described:
XIAP, CIAP1, CIAP1, Apollon, Livin, Survivin,
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quires the presence of one or more baculoviral IAP
repeat (BIR) domains. CIAP1, CIAP2 and XIAP
each contain three BIR domains whereas ML-IAP
and Apollon contain only one (Reviewed in Nach-
mias et al., 2004).
Caspase inhibitory properties have been described
for at least ﬁve IAP family members – CIAP1,
CIAP2, XIAP, ML-IAP (Livin) and Apollon. In
experimental systems, overexpression of IAP proteins
enhances resistance to radiation and a range of che-
motherapeutic drugs (Liston et al., 1996; Duckett
et al., 1998; Tamm et al., 1998; Jin et al., 2004).
Furthermore, increased expression levels of IAP
proteins correlates with poor prognostic outcomes in
multiple neoplastic diseases (Tamm et al., 2000,
2004).
IAP proteins inhibit caspases through multiple
potential mechanisms. XIAP, CIAP1, CIAP2 and
Livin each possess a RING domain which may act
as an E3 ligase to facilitate the proteosomal degra-
dation of protein partners such as caspases, Smac
and Omi/Htra2 (reviewed in Vaux and Silke, 2005).
The factors governing this indirect caspase repres-
sion mechanism are poorly understood. In contrast,
the molecular basis for direct inhibition of caspases
has been methodically delineated through a combi-
nation of structural and biochemical studies (Chai et
al., 2000, 2001; Liu et al., 2000; Wu et al., 2000;
Huang et al., 2001; Riedl et al., 2001; Shiozaki et al.,
2003).
The linker-BIR2 domain from XIAP has high
aﬃnity (Kd = 35 nM) for caspases 3 and 7 and
inhibits these caspases by binding across their active
sites and denying substrate access (Chai et al., 2001;
Huang et al., 2001; Riedl et al., 2001). XIAP BIR3
inhibits caspase 9 by binding caspase 9 monomers
and interfering with dimerization-based caspase 9
activation (Shiozaki et al., 2003). This inhibition is
mediated through the interaction of a hydrophobic
pocket on the surface of XIAP BIR3 with the IAP
binding motif (IBM) or ATPF which becomes
exposed upon proteolytic activation of caspase 9
(Srinivasula et al., 2001). While a second interface
between caspase 9 and XIAP BIR3 has been
described, the interaction between the IBM and the
BIR3 peptide binding pocket is critical (Shiozaki
et al., 2003). Active caspase 9 that is engaged by BIR3
is unable to bind and cleave substrate.
XIAP is by far the best characterized IAP family
member and most eﬀective of all the IAPs at caspase
inhibition. Indeed, the caspase inhibitory properties
intrinsic to the BIR domains of CIAP1, CIAP2,
Apollon and Livin are controversial. The aﬃnity of
CIAP1 and CIAP2 BIR2 and BIR3 domains for
caspase 3/7 and caspase 9 respectively are at least an
order of magnitude less than that of XIAP (Deveraux
et al., 1998). The single BIR domain from ML-IAP
(Livin) reportedly can inhibit caspases 3, 7 and 9
(Ashhab et al., 2001; Kasof and Gomes, 2001; Vucic
et al., 2000, 2002, 2005). Apollon reportedly can
directly inhibit caspase 9 and may regulate the
turnover of caspases 3/7 via proteosomal degradation
(Qiu et al., 2005).
The ability of IAP proteins to buﬀer an apoptotic
signal is subject to regulation by Smac/Diablo, a
mitochondrial protein initially discovered as an XIAP
interacting protein partner (Du et al., 2000; Verhagen
et al., 2000). One well deﬁned interaction interface
maps to the amino terminus of Smac and the caspase
9-binding surface groove of XIAP BIR3. The mini-
mal BIR3-binding region of Smac has been localized
to the extreme amino terminus of proteolytically
processed Smac, a region which shares homology to
the IBM of caspase 9. Biochemical and protein–
protein interaction assays demonstrated that occu-
pancy of the BIR3 surface groove by Smac or
Smac-derived peptides prohibits the BIR3–caspase 9
interaction (Srinivasula et al., 2001).
The observation that short Smac-derived peptides
could inhibit the caspase 9–BIR3 interaction in vitro
hinted at a therapeutic utility for Smac. Agents
which, like Smac, could disengage IAPs from casp-
ases would be predicted to hypersensitize cancer cells
to apoptotic stimuli. Indeed, delivery of Smac pep-
tides into tumor cell lines or tumor xenografts
through the use of Tat and Penetratin peptide fusions
was found to exacerbate apoptosis induced by a
spectrum of agents including Taxol, Doxorubicin and
Trail (Arnt et al., 2002; Fulda et al., 2002; Vucic
et al., 2002; Yang et al., 2003).
While these proof of concept studies galvanized
interest in Smac as a therapeutic approach, these early
reagents were inadequate as clinical entities. Eﬀorts
are in place in many laboratories to distill the biologic
properties of Smac down to adrug-like small molecule
for cancer therapy. The complexities of this challenge
are emblematic of protein–protein interaction targets.
Unlike typical enzyme/substrate interactions, pro-
tein–protein interactions generally span large ﬂat
surfaces and lack deep, deﬁned binding pockets
(Sharma et al., 2002). Disruption of protein–protein
interactions is thus a formidable task for a small
molecule.
22 Sharma, Straub, and ZawelProtein–protein targets of biological relevance are
‘‘drugable’’ if they are amenable to intervention by a
small molecule resulting in a desired biological
response. This novel small molecule must be potent,
speciﬁc, metabolically stable, and preferably orally
active with good pharmacokinetics and no toxicity.
Structural information of the involved protein/pro-
tein interface is necessary not only to design a small
molecule inhibitor of protein-protein interaction but
also for providing further insight in the development
of antagonist molecules by optimization of HTS hits.
Even though it is relatively easy to identify peptide
leads (8–12 amino acids), these leads usually suﬀer
from poor stability and bioavailability. Furthermore,
converting these peptide leads to small drug-like
molecules presents a huge undertaking.
It appears from the published structures of BIR3-
XIAP bound to either Smac peptide or protein, that
inhibition of IAPs is indeed feasible using small
peptides, as binding involves relatively few interface
residues (Liu et al., 2000; Wu et al., 2000). Here, we
describe a systematic study that was undertaken to
explore the physical and chemical binding charac-
teristics of the Smac peptide–BIR3 interaction. We
deﬁned the smallest possible biologically active pep-
tide capable of high aﬃnity binding to the BIR3
peptide pocket. The development and characteriza-
tion of the ﬁrst generation of small molecule Smac
mimetics is described. This work represents the pri-
mary SAR for the future design of Smac mimetics.
RESULTS: SMAC/XIAP INTERACTION:
DETERMINATION OF OPTIMAL LIGANDS
FOR THE BIR3 PEPTIDE BINDING POCKET
Peptide–BIR3 Binding Assay
To rapidly proﬁle compounds for their ability to
bind the BIR3 peptide-binding pocket, a solution
phase assay was developed based on FMAT
technology (Lee et al., 2003). Brieﬂy, biotinylated
Smac 7-mer peptide (AVPIAQK, lysine e-amino
group is biotinylated) was immobilized on streptavi-
din coated beads. GST–BIR3 fusion protein was
precipitated with FMAT beads in a manner strictly
dependent on Smac peptide and could be detected
using ﬂuorescent tagged anti-GST antibodies.
Importantly, non-biotinylated Smac peptide was
highly eﬀective at competing GST–BIR3 oﬀ the
FMAT beads. The IC50 for non-biotinylated Smac
was 400 nM. IC50 values for synthetic peptides were
determined using this assay.
Minimum Sequence Requirement
Several shorter Smac-derived peptides starting
from AVPIAQK (7-mer down to 3-mer) were
synthesized and tested as described above (Table I).
In all of these peptides, the N-terminal alanine was
kept invariant and the length was changed at the
C-terminal end. In addition, 4-mer peptides including
Reaper, Hid, and Grim (derived from Drosophila)
were also synthesized. In order to facilitate the rapid
synthesis of these peptides, a solid phase approach
was employed starting with Fmoc-Rink amide resins.
Final cleavage of the peptide from the resin provides
compounds containing C-terminal amides instead of
acids, thus it should be noted that all peptides pre-
pared contain this C-terminal amide unless otherwise
noted. Our results indicate that inhibitory activity of
peptides is maintained with N-terminal 4 amino acid
containing peptides (IC50 range 270–580 nM) and
conﬁrm the observations made earlier by structural
studies (Chai et al., 2000, 2001). The N-terminal
tripeptide, however, loses its ability to inhibit Smac–
BIR3 interaction (AVP, IC50>10lM).
An alignment of all IAP binding proteins,
including from Drosophila, provided a consensus
sequence AVPF (Table II) with Phe as the consensus
residue at the 4th position. It was no surprise that this
4-mer had the best inhibitory activity against the
Smac–BIR3 interaction. Therefore, amino acid
replacements were performed using the consensus
sequence AVPF with N-terminal carboxamide.
Alanine Replacements in AVPF
Alanine was replaced with other carefully chosen
hydrophobic amino acids containing various size side
chains including a-aminobutyric acid (Abu), serine
(Ser), a,a-dimethylglycine (Dmg), a-cyclopropylgly-
cine (Cpg), a-cyclohexylglycine (Chg) (Table III). We
observed loss of inhibitory activity for all synthesized
Table I. Minimum Inhibitory Sequence
Compound # Sequence* Source protein IC50 (lM)
1 AVPIAQK Smac 0.39
2 AVPIAQ Smac 0.27
3 AVPIA Smac 0.30
4 AVPI Smac 0.58
5 AVP Smac >10.00
6 AVAF Reaper 0.75
7 AVPF Hid 0.12
8 AIAY Grim 0.34
*Indicates sequences terminate as C-terminal primary amide.
**Indicates the highest concentration tested.
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These results suggest that the binding pocket around
the methyl side chain of Ala is quite small. This
observation is consistent with previous structural
studies that showed that alanine replacement with
methionine causes loss of inhibitory activity (Liu
et al., 2000; Wu et al., 2000). However, substituting
an ethyl to methyl side chain (Abu) resulted in
enhanced inhibition suggesting that additional space
exists in the pocket around this residue. Added van
der Waals interaction with the extra methylene group
in the hydrophobic pocket may be responsible for
increased inhibitory activity. In addition, the func-
tional role of amino group of Ala was assessed by the
replacement of the a-amino group with a hydroxyl
group (Lac for Ala), compound 14. This substitution
for the a-amino group resulted in total loss of
inhibitory activity of the 4-mer suggesting the critical
role of the a-amino group in forming three hydrogen
bonds with BIR3 pocket residues (Chai et al., 2001).
Valine Replacements in AVPF
Previously, alanine scans of Smac-derived pep-
tides indicated that Val could be replaced by other
hydrophobic amino acids (Liu et al., 2000; Wu et al.,
2000). The isopropyl side chain of Val makes
important hydrophobic contacts with W310 residue
of BIR3 domain. We synthesized and analyzed sev-
eral 4-mer peptides using other hydrophobic amino
acids to maximize this interaction. In all cases with
the exception of Cpg, the inhibitory activity of the
parent 4-mer was maintained (IC50 range 0.08 vs.
0.20 lM) with Ile as the best replacement (Table III).
This result with Cpg is not surprising as it involves a
a,a-disubstituted amino acid (steric bulk at a-car-
bon). Recently, Arg was reported as the best
replacement at this position (Kipp et al., 2002).
Proline Replacements in AVPF
Proline seems to play an important role in
establishing the b-strand conformation of Smac
peptides when bound to the BIR3 domain (Chai
et al., 2000, 2001). Thus, we made a few conservative
Pro replacements in this study (Table III). Only two
replacements were used for optimization, including
Hyp and Pip (a 6-membered homolog of Pro).
Replacement of Pro to Pip and Hyp in the parent
4-mer resulted in loss of some inhibitory activity
(IC50 0.12 vs. 0.75 and 1.0 lM, respectively). Our
Smac–BIR3 binding model suggests that the intro-
duction of a hydroxyl group on the proline ring may
disturb the hydrophobic contact established with the
nearby W310. Even though this loss of activity is
signiﬁcant, Ala is present in this position in other
natural IAP inhibitors, including Grim and Reaper,
suggesting changes at this position would be allowed.
Phenylalanine Replacements in AVPF
Phe, the consensus residue at the 4th position,
forms van der Waals contacts with BIR3 pocket res-
idues. This implies that any aliphatic or aromatic
amino residue at this position would be allowed. In
addition, Fesik and co-workers showed that inhibi-
tory activity of a 7-mer peptide is retained when Ala is
substituted for Phe (Liu et al., 2000). Analogs syn-
thesized from this series included naturally occurring
4-mer peptides derived from either Smac (AVPI), Hid
(AVPF), and Grim (AIAY) (Table III). Although all
Table II. Consensus Sequence
IAP binding protein Sequence
Smac A–V–P–I
Hid A–V–P–F
Grim A–I–A–Y
Reaper A–V–A–F
Sickle A–I–P–F
Consensus A–V–P–F
Table III. Amino Acid Replacements
Compound # Sequence* IC50 (lM)
Ala replacements
9 Abu–VPF 0.12
10 SVPF 1.00
11 Dmg–VPF >1.6
12 Cpg–VPF >1.6
13 Chx–VPF >1.6
14 Lac–VPF >1.6
Val replacements
15 ALPF 0.18
16 AIPF 0.08
17 ATPF 0.20
18 A–Cpg–PF >1.6
19 AFPF 0.19
Pro replacements
20 AV–Hyp–F 1.0
21 AV–Pip–F 0.71
Phe replacements
4 (Smac 4-mer) AVPI 0.58
7 (Hid 4-mer) AVPF 0.12
8 (Grim 4-mer) AIAY 0.34
N-Methylamides
22 A–(N-Me)VPF > 1.6**
23 AVP–(N-Me)F 0.38
*Indicates sequences terminate as C-terminal primary amide.
**Indicates the highest concentration tested.
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interaction, our results further conﬁrmed that Phe at
this position is the most optimal residue.
N-Methyl Amide Analogs of AVPF
The consensus 4-mer peptide AVPF has two sec-
ondary amide bonds. Two analogs with (N-Me)-Val
and (N-Me)-Phe (Table III) were synthesized in a
similar manner as described for AVPF using Fmoc-
(N-Me)Val or Fmoc-(N-Me)Phe, respectively. With
these modiﬁcations, we analyzed the signiﬁcance of
H-bond contributions of the amide NHs. An alkyl-
ation of these NHs without loss of inhibitory activity
wouldfacilitatefurthermimeticdesign.N-methylation
of Val resulted in total loss of inhibitory activity of
the parent compound (IC50 0.12 vs. >1.6 lM) indi-
cating the critical role of this NH in forming a H-bond
with BIR3 pocket residues. However, N-methylation
of Phe retained signiﬁcant activity (loss of activity by
3-fold, IC50 0.12 vs. 0.38 lM). Though this amide NH
is involved in H-bond, our result suggests that this
amide can be replaced, if desired, for mimetic designs.
Manipulation of the N-terminus in AVPF
Several analogs of the AVPF 4-mer in which sub-
stitution on the N-terminus of alanine was varied were
synthesizedinasimilarmannerasdescribedforAVPF.
With these modiﬁcations we examined the signiﬁcance
of the H-bond contributions of the terminal amine.
N-methylation of the alanine residue provided 24
which exhibited a 2-fold increase in inhibitory activity
of the parent compound (IC50 0.12 vs. 0.075 lM). On
the other hand, single alkylation of the parent with
othergroupsresultedinprecipitouslossofactivity(Et:
IC50 =4lM; cyclopropyl methyl: IC50 = 1.5 lM;
cyclohexyl methyl: IC50 =2lM). It was also
observedthatdoublealkylation of thealanineresulted
in complete loss of activity (N,N-dimethyl Ala IC50 >
10 lM), suggesting that this residue is involved in
crucial hydrogen bonds in the BIR3 pocket.
An overview of the observed SAR is presented in
Fig. 1, and a working model for the interactions of
the AVPI fragment based on published X-ray and
NMR structural data (Chai et al., 2000, 2001) is
shown in Fig. 2.
Functional Analysis of 4-mer Peptides
Results described thus far suggest that Smac’s
BIR3 binding activity is preserved in a 4-mer peptide
(relative to Smac 7-mer) provided that Phe was
substituted for Ile at position 4. In order to assess
whether these alterations had functional conse-
quence, DEVD cleavage assays were performed in the
presence of recombinant GST–BIR3. In these assays,
caspase 3 activity present in 293 cell cytoplasmic ex-
tracts was monitored using the ﬂuorescent-tagged
synthetic substrate DEVD-AMC. While this is the
optimal peptidic caspase 3 substrate, DEVD cleavage
still requires caspase 3 processing by active caspase 9.
BIR3 inhibits caspase 9 and this results in the inhi-
bition of DEVD cleavage. As shown in Table IV, this
inhibition is overcome by Smac 7-mer (AVPIAQK,
IC50 =3lM). Substitution of Phe for Ile slightly
enhanced potency (AVPFAQK, IC50 =2lM).
Interestingly, 4-mer peptide AVPF was as active as
Phe-containing Smac 7-mer (AVPIAQK) (Table IV).
Optimization for Cellular Activity
At this point, although we had demonstrated
potent activity against the target in binding assays,
these compounds were devoid of any signiﬁcant cel-
lular activity (i.e., in proliferation assays). Suspecting
that the lack of activity related to the inability of
these molecules to penetrate the cells, we undertook
an eﬀort to remove dispensable charged residues and
introduce hydrophobic fragments into the molecules
where tolerated. Our ﬁrst step was to remove the
primary amide present on the Phe residue, giving
compound 25 (Fig. 3). This resulted in a signiﬁcant
increase in cellular activity from >10 to 1 lM.
Previously discussed SAR suggested portions of the
molecule that could be altered to introduce hydro-
phobicity. This led to the synthesis of compound 26
in which the proline was substituted with a cyclohexyl
methyl amine at the 4 position, and compound 27 in
which the phenethyl amine was changed to a 1-benzyl
2-phenethyl amine. These alterations changed the
cLogP of the molecules from 1.1 for 24 and 2.2 for 25
to 3.9 and 4.4 for 26 and 27 respectively. This resulted
in cellular activity of 0.6 lM for 26 and 0.25 lM for
27 (Table V). Anti-proliferative activity was abro-
gated by co-incubation of compounds with a pan-
caspase inhibitor, consistent with cell death occurring
via apoptosis (data not shown).
Analysis of the X-ray Structures of 26 with XIAP
BIR3
Co-crystallization yielded a 1.6 A ˚ resolution
X-ray structure of a truncated XIAP BIR3 domain
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ﬁrmed much of the SAR that had been obtained in
our eﬀorts to minimize and optimize the 7-mer
peptide. The N-terminus Ala is involved in a potent
hydrogen bond to Glu314. The increase in activity
against XIAP seen with the methylated peptide ap-
pears to be the result of the increase of the pKao f
this residue when it is alkylated, while the decrease
in activity seen with larger alkyl substituents is most
likely due to steric interference with Lys311, bor-
dering this section of the pocket. The methyl group
of the Ala residue ﬁlls a hydrophobic pocket deﬁned
by Gln319, Trp310 and Leu307. The small size of
this pocket explains the rather limited substitutions
tolerated in this portion of the molecule. The Val
nitrogen is hydrogen bonded to Thr308, while the
Fig. 1. SAR of Smac 4-mer, AVPI.
Fig. 2. Binding of Smac 4-mer AVPI in BIR3 pocket. The green dotted lines indicate H-bonding.
26 Sharma, Straub, and Zawelside chain i-Pr group is solvent exposed, thus sug-
gesting another portion of the molecule that could
be altered to provide improved cellular penetration.
The Pro residue has edge on hydrophobic contact
with Trp323 and Tyr324 and also provides the
b-turn required to orient the phenyl group of the
C-terminus of both molecules into the hydrophobic
pocket deﬁned by Gly305 and Gly306. The second
phenyl ring of 26 is exposed to solvent, allowing for
the substitution of other hydrophobic groups to
further improve cellular penetration. It also appears
that cis substituents at the 4 position of the proline
ring are exposed to solvent, thus explaining the
increased cellular activity seen with 27.
Smac Mimetics Inhibit Assembly of Native Caspase
9–XIAP Complexes
Having ﬁrmly established that these analogs were
capable of binding to the hydrophobic pocket of
XIAP BIR3, we next assessed whether compound 27
could interfere with the formation of native XIAP–
caspase 9 complexes in cell extracts. In hypotonic 293
extracts, activation of caspase 9 is triggered by the
addition of cytochrome C and dATP (lanes 1 and 2).
As reported previously (Srinivasula et al., 2001) only
the cleaved form of caspase 9 coimmunoprecipitated
with XIAP (Fig. 5, lanes 3 and 4) and this was
dependent on cytochrome C stimulation. Addition of
27 to the extracts inhibited the recovery of caspase 9
from XIAP immunoprecipitates. 27 was slightly more
eﬀective than Smac 7-mer in blocking the XIAP–
caspase 9 interaction (compare lanes 6 and 8). A
related 4-mer peptide (28) lacking detectable BIR3
binding activity (IC50 > 50 lM), was without eﬀect
in XIAP–caspase 9 coimmunoprecipitations (lane 9).
Thus, these ﬁrst generation Smac mimetic
Table IV. Functional Assay with IAP Binding Peptides
Sequence IC50 (lM)
AVPIAQK 3.0
AVPFAQK 2.0
AVPF 2.0
Fig. 3. Structures of Novartis inhibitors.
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occupancy of the XIAP BIR3 surface groove.
DISCUSSION AND CONCLUSIONS
Target-based therapeutic strategies for cancer
treatments continue to evolve. Many protein–protein
interaction targets have been identiﬁed for cancer
therapy including apoptotic signaling targets. Recent
structural studies have identiﬁed inhibition of the
caspase–IAP interaction as an attractive target for
cancer intervention. The BIR2 and BIR3 domains of
XIAP directly interact with and inhibit caspase 3/7
and caspase 9, respectively. Smac is a naturally
occurring antagonist of the caspase–IAP interaction.
Full length Smac appears necessary for neutralizing
BIR2, while short 4–7-mers derived from the Smac
amino terminus are suﬃcient for overcoming BIR3-
mediated repression. As inhibition of protein–protein
interactions often requires larger peptides unamena-
ble to small molecule conversion, targeting BIR3-
caspase 9 represents a unique opportunity for drug
developers. This almost certainly explains why al-
though several small molecule BIR2 inhibitors have
been described (Wu et al., 2003; Schimmer et al.,
2004), the eﬀort to develop BIR3 inhibitors has been
more intense thus far.
The structural features underlying Smac–BIR3
binding have been elucidated with both full length
Smac protein and Smac 9-mer peptide by X-ray and
NMR, respectively (Liu et al., 2000; Wu et al., 2000).
Smac binding to the BIR3 domain involves two dis-
tinct binding interfaces. The ﬁrst interface involves
the N-terminal four residues of Smac (small interface,
size 892 A ˚ 2), while the second involves the middle
portion of Smac (large interface, size >2000 A ˚ 2).
Mutational studies have determined that the ‘‘hot
spot’’ residues – those which contribute to maximal
binding energy (Sharma et al., 2002) – are localized at
the N-terminus of Smac (Liu et al., 2000; Wu et al.,
2000).
Using X-ray crystallography, NMR binding
analyses, CAMM, and a systematic, position by po-
sition chemical optimization strategy we and others
have extended these studies in pursuit of a biostable,
cell permeable, small molecular weight Smac mimetic
compounds (Kipp et al., 2002; Franklin et al., 2003;
Li et al., 2004; Oost et al., 2004; Sharma et al., 2004;
Sun et al., 2004a, 2004b).
The molecules which have emerged from these
eﬀorts share numerous structural features (see
Figs. 3, 6 and 7). The amino-terminal alanine is
essentially invariant. This residue makes several crit-
ical H-bonds with BIR3 residues (Fig. 2). Methyla-
tion of the amino terminal nitrogen increases the
BIR3 binding potency by ﬁlling a mini-hydrophobic
Table V. Cellular Proliferation Assay, SKOV3 Cells
Compound # IC50 (lM)
24 > 10.0
25 0.9
26 0.6
27 0.25
Fig. 4. X-ray structure of compound 26 co-crystallized with the BIR3 domain of XIAP.
28 Sharma, Straub, and Zawelpocket (Gln319, Trp310 and Leu307) and may have
an overall stabilizing eﬀect on the peptidomimetic by
reducing exopeptidase access (Kipp et al., 2002). The
Val–Pro sequence in position 2–3 has been shown to
be part of an antiparallel b-sheet binding conforma-
tion resulting from H-bonds formed with the b-sheet
residues of the BIR3 pocket. Pro forms a kink in the
peptide backbone and directs the hydrophobic side
chain of the 4th residue (Ile) of Smac into the
hydrophobic cleft of BIR3, deﬁned by Gly305 and
Gly306. Lack of activity of the tripeptide (AVP)
suggests this hydrophobic interaction is essential for
binding potency.
Sun et al. succeeded in further depeptidizing the
mimetic by cyclizing the valine and proline residues
to give the fused bicyclic core of structures 34 and 35
(Sun et al., 2004a, 2004b). Application of the SAR
developed previously resulted in 34 which exhibits a
Ki of 350 nm as determined in a ﬂuorescence polari-
zation (FP) assay. The decrease in binding aﬃnity vs.
Fig. 5. Disruption of native XIAP–caspase 9 complexes.
Fig. 6. Structures of Abbott IAP inhibitors.
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bicyclic scaﬀold imparts on the side chains when
bound to XIAP. Increasing the size of the 6-mem-
bered ring by one carbon provided the 7/5 fused
structure 35 which perfectly mimics the conﬁrmation
of the Smac tetrapeptide. This alteration resulted in a
Ki of 25 nM, a 14-fold increase in the binding aﬃnity
vs. 34 and a 4-fold increase vs. AVPI. It is important
to note that only the indicated stereochemistry at the
proline junction is tolerated, as this provides the
proper orientation of the side chains to preserve the
hydrogen bonding and hydrophobic interactions of
the Smac/XIAP interface.
The greatest diversity among Smac mimetics in-
volves variation at the C-terminus. Substituents at
this position have the potential to pick up hydro-
phobic interactions with BIR3 and may also be sol-
vent exposed, allowing for attachment of substituents
which can modulate cellular permeability. Whereas
we found phenethyl to provide a balance of BIR3
binding and cellular potency, others obtained similar
results with a tetrahydronapthyl group (Oost et al.,
2004) or an a-phenylbenzylamine (Sun et al., 2005).
Interestingly, dimerization of Smac mimetic
compounds was found to signiﬁcantly enhance BIR3
binding and cellular potency (Li et al., 2004). This is
perhaps not surprising as natural Smac was found to
homodimerize (Chai et al., 2000). What remains un-
clear is the precise binding mode for small molecular
weight dimers. Does the dimer engage BIR3 domains
from two separate IAP molecules or does the dimer
induce a conformational change in a single IAP
molecule allowing simultaneous binding to BIR2 and
BIR3? A crystal structure of these dimers in complex
with native XIAP is necessary to resolve this question.
The structural homogeneity of the compounds
referenced above stems from the commonality of the
approach used for their derivation. Two noteworthy
approaches which deviated from this strategy yielded
highly unique BIR3-binding compounds.
Wang and coworkers exploited the BIR3–Smac
X-ray structure by employing it in a virtual docking
screen of a 3D structure database comprising 8200
small organic molecules isolated from traditional
Chinese medicinal herbs. Using a consensus scoring
program in conjunction with the DOCK program
they narrowed the possibilities to 200 high scoring
compounds. The most potent compound tested was
Embelin, exhibiting an IC50 of 4.1 lM. Binding of
Embelin to the XIAP BIR3 domain was conﬁrmed
via HSQC NMR studies with
15N labeled protein
(Nikolovska-Coleska et al., 2004).
Fig. 7. Structures of University of Michigan IAP inhibitors.
30 Sharma, Straub, and ZawelFesik and colleagues similarly embraced a non-
traditional peptidomimetic approach by synthesizing
several libraries in which the terminal alanine residue
was held constant and linked to fragments that could
form hydrogen bonds with the XIAP BIR3 domain
(Park et al., 2005). The most potent leads (determined
by both NMR binding studies and the FP assay) were
further optimized based on the structural information
known about peptides bound to the BIR3 domain.
This approach led to the synthesis of 31 with a Kd of
740 nM. NMR binding studies revealed a binding
motif for the N-terminal alanine which was similar to
that seen with the tripeptides above. In addition, it
was observed that the amide between the alanine and
the thiazole provides contact to the carbonyl of
Thr308, while the phenyl group in the 5 position of
the thiazole ﬁlls the hydrophobic pocket occupied by
the proline of the tripeptides and the 4-bromo-phenyl
group is pointing towards the hydrophobic grove
ﬁlled by the isoleucine of Smac.
Based on their assumed mechanism of action,
Smac mimetics would be predicted to lower the
threshold for apoptotic cell death. Here 4-mer pep-
tides were capable of restoring DEVD cleavage
activity to BIR3-inhibited cytoplasmic extracts. Smac
mimetics from other laboratories have been found to
synergize with TNF and Trail (Li et al., 2004; Sun
et al., 2004a, 2004b) and in certain cases, to induce
cell death as single agents (Oost et al., 2004). Com-
pound 29 was reported to display nanomolar potency
in breast (BT-549, MDA-MB-231), leukemia (HL-60)
and renal (RXF-393) lines, and low micromo-
lar activity in melanoma (SK-MEL-5), ovarian
(SK-OV-3) and the NSCLC lines NCI-H23 and NCI-
H522 (Oost et al., 2004). Furthermore, several of the
optimized compounds displayed eﬃcacy in a subcu-
taneous MDA-MB-231 xenograft model when dosed
daily at 20–40 mg/kg/day (Oost et al., 2004). Inter-
estingly, no correlation between the observed potency
and XIAP expression exists, thus other factors may
be involved. Understanding the contextual basis for
these responses may well be the secret to successful
implementation of this therapeutic strategy.
Future challenges will be to convert these peptides
to small drug-like molecules for cancer therapy. We
are conﬁdent that by utilizing a peptidomimetic
approach, we can produce bioavailable molecules
which will potently inhibit IAP proteins, thereby
providing a novel method of enhancing the eﬀec-
tiveness of many of the currently available therapies
for treating cancer.
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